TREMFYA® demonstrates long-term skin clearance in psoriasis

New data demonstrates long-term skin clearance in patients with moderate to severe plaque psoriasis treated with Janseen’s TREMFYA® (guselkumab).

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced new data that showed a vast majority of patients with moderate to severe plaque psoriasis receiving TREMFYA® (guselkumab), who achieved at least a 90 percent improvement in the Psoriasis Area and Severity Index (PASI 90) at week 28, maintained a PASI 90 response with continuous treatment through week 72.

Findings from the study also demonstrated that a vast majority of patients originally randomised to guselkumab, but withdrawn from treatment at week 28, regained a PASI 90 response within six months of initiating guselkumab retreatment.

Results from the trial demonstrated that among patients who achieved a PASI 90 response at week 28 with guselkumab, 86 percent who continued receiving guselkumab maintained a PASI 90 response through week 72, while only 11.5 percent of patients who were withdrawn from treatment maintained a PASI 90 response. Of the 173 patients who were withdrawn from receiving guselkumab, 87.6 percent achieved a PASI 90 response within six months of commencing retreatment.

“The longer-term data from VOYAGE 2 shows promising results for guselkumab as both a continuous, long-term treatment for moderate to severe plaque psoriasis, and as an option for patients who have been wi­thdrawn from therapy and retreated,” said study investigator Prof. Kristian Reich, M.D. of Dermatologikum Berlin and SCIderm Research Institute in Hamburg, Germany. “These data provide important information to dermatologists should they need to interrupt treatment with guselkumab for a period of time, as the findings demonstrate guselkumab quickly and robustly re-established a PASI 90 response within six months.”